Navigation Links
Convergen LifeSciences Announces Patent Award
Date:7/14/2011

AUSTIN, Texas, July 14, 2011 /PRNewswire/ -- Convergen LifeSciences, Inc. announced today that another United States Patent 7,977,468 has been awarded by the U.S. Patent and Trademark Office jointly to The University of Texas System Board of Regents and The Secretary, U.S. Department of Health and Human Services.  The patent is one of 23 patents, pending or issued worldwide, licensed exclusively to Convergen LifeSciences, Inc. The patent covers CNVN202, a targeted molecular cancer therapy undergoing clinical evaluation in lung cancer patients.

The '468 patent is based upon important discoveries made by a team of researchers from The University of Texas MD Anderson Cancer Center, The University of Texas Southwestern Medical Center and the National Cancer Institute. The discovery of the 3p21.3 family of tumor suppressor genes has been the subject of more than 20 peer-reviewed scientific publications demonstrating the genes' ability to control key anti-cancer mechanisms.  CNVN202 harnesses TUSC2 (FUS1), the most potent inducer of apoptosis among the family of 3p21.3 cancer suppressor genes.

"The patent further solidifies our growing IP portfolio," stated Greg Heinlein, Chief Operating and Financial Officer, Convergen LifeSciences. "Broadly speaking, this patent expands the application of CNVN202 to virtually all cancers and extends the use of our patented technologies to include cancer diagnostic and screening tools."

Data from a phase I clinical study presented at the 2011 annual meeting of the American Association for Cancer Research showed for the first time that a tumor suppressor gene can be delivered intravenously and selectively to human cancer cells using a nanoparticle vector, express high levels of mRNA and protein in cancer cells in the primary tumor and distant metastatic sites, alter relevant pathways in the cancer cell and mediate clinically beneficial anti-cancer activity.

A phase II clinical trial is planned to evaluate CNVN202 in combination with Tarceva® (erlotinib) in lung cancer patients who would not be expected to benefit from erlotinib alone.   CNVN202 has shown synergy when combined with erlotinib in both EGFR mutation positive and negative cancers.

Tarceva® is a registered trademark of the Roche Group including Genentech and Chugai and Astellas Pharma.  

Contact:
Greg Heinlein
Convergen LifeSciences, Inc.
(512) 372-4422
Email: gheinlein@convergenlifesciences.com
www.convergenlifesciences.com


'/>"/>
SOURCE Convergen LifeSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Drug Device Combination Market to 2016 - Technological Convergence to be the New Business Model for Growth and Profitability
2. Interdisciplinary Convergent Approach May Represent Future for Treatment of Atrial Fibrillation
3. Thought Leaders Shaping the Emerging Wireless Life Science Space to Share Vision and Insights at WLSA Convergence Summit
4. Perceptive Informatics Introduces Greater Convergence Between EDC and RTSM Solutions in Its eClinical Suite
5. nContact Announces Initiation of Clinical Trials for the Treatment of Paroxysmal Atrial Fibrillation Utilizing New Convergent Ablation Procedure
6. CPhI 2009: Madrid Launch for BioPh Marks Pharma and Biotech Convergence
7. TCG Lifesciences Expands Pharmaceutical, Biotechnology Research Initiatives with CAS SciFinder®
8. Lifesciences IT Spending to Experience Mature Growth Rates Despite Economic Slowdown, Declares Frost & Sullivan
9. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
10. Neuralstem Announces Notice of Allowance for Two Additional Neurogenic Compound Patents
11. Vapotherm Announces Approval in Canada for New High Flow Device Designed for Heliox
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... , Feb. 17, 2017   Risperdal lawsuits involving ... allegedly associated with use of the atypical antipsychotic medication ... Court of Common Pleas, where the state,s ... program. According to a notice posted on the ... a meeting on March 9, 2017 at 11:00 a.m. ...
(Date:2/17/2017)...   FormFast , the leader in electronic forms ... Engage , one of the largest MEDITECH partners ... will serve as the forms automation and electronic signature ... .  FormFast is a MEDITECH collaborative ... enhance the electronic health record. FormFast,s technology bridges clinical ...
(Date:2/17/2017)... Feb. 17, 2017  BioDigital, Inc., creators of ... of their 3D body mapping technology with eClinicalWorks, ... new integration will be used to capture and ... of the human body. BioDigital pilots show using ... while also increasing the precision of clinical annotations ...
Breaking Medicine Technology:
(Date:2/18/2017)... Waltham, Massachusetts (PRWEB) , ... February 17, 2017 ... ... be the leading source of disruptive innovation in the industry, according to the ... Insights Reports are based on surveys of the NEJM Catalyst Insights Council, a ...
(Date:2/18/2017)... MANDEVILLE, La. (PRWEB) , ... February 18, 2017 ... ... Network released today provides the latest information and contact points to easily connect ... including home care, assisted living, and elder-care funding. It also conveys material on ...
(Date:2/17/2017)... ... 2017 , ... For the first time, International Scholarship and ... floor for the 2017 HIMSS Conference & Exhibition at the Orange ... than 40,000 healthcare industry professionals are expected at the conference, where they will ...
(Date:2/17/2017)... Texas (PRWEB) , ... February 17, 2017 , ... ... 8.0 at the HIMSS17 Conference & Exhibition in Orlando, Fla., February 19-23. Visitors ... version of the most widely used electronic patient signatures solution in healthcare ...
(Date:2/17/2017)... ... February 17, 2017 , ... Cancer diagnostics workflow solution ... February 20 – 22 in San Francisco. As part of the Tri-Conference expo, ... pathology workflow solution, as well as its new precision medicine platform, “Crosswalk Insight: ...
Breaking Medicine News(10 mins):